1-Aryl-3-(1-acylpiperidin-4-yl)urea Inhibitors of Human and Murine Soluble Epoxide Hydrolase: Structure−Activity Relationships, Pharmacokinetics, and Reduction of Inflammatory Pain
- 2 September 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (19), 7067-7075
- https://doi.org/10.1021/jm100691c
Abstract
1,3-Disubstituted ureas possessing a piperidyl moiety have been synthesized to investigate their structure−activity relationships as inhibitors of the human and murine soluble epoxide hydrolase (sEH). Oral administration of 13 1-aryl-3-(1-acylpiperidin-4-yl)urea inhibitors in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-adamantylurea based inhibitors. For example, 1-(1-(cyclopropanecarbonyl)piperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (52) showed a 7-fold increase in potency, a 65-fold increase in Cmax, and a 3300-fold increase in AUC over its adamantane analogue 1-(1-adamantyl)-3-(1-propionylpiperidin-4-yl)urea (2). This novel sEH inhibitor showed a 1000-fold increase in potency when compared to morphine by reducing hyperalgesia as measured by mechanical withdrawal threshold using the in vivo carrageenan induced inflammatory pain model.Keywords
This publication has 50 references indexed in Scilit:
- Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogsEuropean Journal of Pharmaceutical Sciences, 2010
- Soluble Epoxide Hydrolase in AtherosclerosisCurrent Atherosclerosis Reports, 2010
- Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseasesNature Reviews Drug Discovery, 2009
- Discovery of potent non-urea inhibitors of soluble epoxide hydrolaseBioorganic & Medicinal Chemistry Letters, 2009
- Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathwaysProceedings of the National Academy of Sciences of the United States of America, 2008
- Orally Bioavailable Potent Soluble Epoxide Hydrolase InhibitorsJournal of Medicinal Chemistry, 2007
- Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitorsProceedings of the National Academy of Sciences of the United States of America, 2006
- Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitorsBioorganic & Medicinal Chemistry Letters, 2006
- Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolaseBioorganic & Medicinal Chemistry Letters, 2006
- High-throughput pharmacokinetic method: Cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysisAnalytica Chimica Acta, 2006